SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
-19.4%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$2.07B
AUM Growth
+$2.07B
(-12%)
Cap. Flow
+$173M
Cap. Flow
% of AUM
8.37%
Top 10 Holdings %
Top 10 Hldgs %
48.47%
Holding
98
New
23
Increased
27
Reduced
24
Closed
17
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$48.8M |
| 2 |
SHPG
Shire pic
SHPG
|
$41.4M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$32.5M |
| 4 |
CELG
Celgene Corp
CELG
|
$32.2M |
| 5 |
Amgen
AMGN
|
$26.7M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$57.3M |
| 2 |
Halozyme
HALO
|
$36M |
| 3 |
Thermo Fisher Scientific
TMO
|
$33.5M |
| 4 |
United Therapeutics
UTHR
|
$30.6M |
| 5 |
Merck
MRK
|
$19.7M |
Sector Composition
| 1 | Healthcare | 95.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $150M | 7.25% | 1,498,738 +321,680 | +27% | +$32.2M |
|
2
Gilead Sciences
GILD
$140B
| $149M | 7.23% | 1,626,764 -155,534 | -9% | -$14.3M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $123M | 5.94% | 1,489,137 +129,215 | +10% | +$10.7M |
|
|
4
Amgen
AMGN
$155B
| $102M | 4.95% | 682,797 +178,200 | +35% | +$26.7M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $91.5M | 4.42% | 657,013 -101,167 | -13% | -$14.1M |
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $83.9M | 4.06% | 232,770 -3,530 | -1% | -$1.27M |
|
7
Incyte
INCY
$16.5B
| $83.6M | 4.04% | 1,153,540 +26,117 | +2% | +$1.89M |
|
8
Amicus Therapeutics
FOLD
$2.34B
| $78M | 3.77% | 9,226,145 +1,252,709 | +16% | +$10.6M |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $71.3M | 3.45% | 896,479 +208,279 | +30% | +$16.6M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $69.7M | 3.37% | 405,347 +240,673 | +146% | +$41.4M |
|
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $65.3M | 3.16% | 1,649,963 +1,233,283 | +296% | +$48.8M |
|
12
Biogen
BIIB
$19.4B
| $61.1M | 2.95% | 234,572 -56,317 | -19% | -$14.7M |
|
|
13
Thermo Fisher Scientific
TMO
$186B
| $52.4M | 2.54% | 370,376 -236,560 | -39% | -$33.5M |
|
|
14
Merck
MRK
$210B
| $39.7M | 1.92% | 749,914 -372,011 | -33% | -$19.7M |
|
15
DexCom
DXCM
$29.5B
| $38.8M | 1.88% | 571,559 +208,826 | +58% | +$14.2M |
|
|
XLRN
16
DELISTED
Acceleron Pharma Inc.
XLRN
| $37.9M | 1.83% | 1,437,235 +315,971 | +28% | +$8.34M |
|
17
Eli Lilly
LLY
$657B
| $36.5M | 1.76% | 506,695 -92,550 | -15% | -$6.66M |
|
18
Medtronic
MDT
$119B
| $35.7M | 1.73% | 475,931 -67,861 | -12% | -$5.09M |
|
|
PTLA
19
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $32.5M | 1.57% | +1,593,039 | New | +$32.5M |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $31.6M | 1.53% | 1,291,153 +356,202 | +38% | +$8.72M |
|
|
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $31.5M | 1.52% | 245,447 +25,400 | +12% | +$3.26M |
|
22
Align Technology
ALGN
$10.3B
| $30.7M | 1.48% | 422,486 +36,382 | +9% | +$2.64M |
|
|
TSRO
23
DELISTED
TESARO, Inc.
TSRO
| $30.4M | 1.47% | 689,869 +284,800 | +70% | +$12.5M |
|
24
Viatris
VTRS
$12.3B
| $27.3M | 1.32% | 589,627 -12,283 | -2% | -$569K |
|
25
Teva Pharmaceuticals
TEVA
$21.1B
| $27.2M | 1.32% | 509,110 -96,812 | -16% | -$5.18M |
|